Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma

Melanoma Research

Volumn 19, Issue 3, 2009, Pages 167-175

  Homsi, Jade ^a   Cubitt, Christopher L ^b   Zhang, Shumin ^b   Munster, Pamela N ^b   Yu, Hua ^c   Sullivan, Daniel M ^b   Jove, Richard ^c   Messina, Jane L ^a   Daud, Adil I ^a,b,d  

^a Cutaneous Oncology ^*  (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d Cancer Center SRB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; CISPLATIN; DASATINIB; PACLITAXEL; PHOSPHOTYROSINE; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE; TEMOZOLOMIDE; TETRAZOLIUM; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; NITRILE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; ASSAY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL GROWTH; CELL LINE; DNA FLANKING REGION; GROWTH INHIBITION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOMA; MUCOSA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN BIOPSY; STAINING; BIOSYNTHESIS; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYMOLOGY; IC 50; PATHOLOGY; PHOSPHORYLATION; SKIN TUMOR; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DACARBAZINE; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; NITRILES; PACLITAXEL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINOLINES; SKIN NEOPLASMS; SRC-FAMILY KINASES; THIAZOLES;

EID: 67849128649     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328304974c     Document Type: Article

References (36)

1. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4:470-480.
2. Yu CL, Meyer DJ, Campbell GS. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269:81-83.
3. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001; 2:467-475.
4. Irby RB, Malek RL, Bloom G, et al. Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype. Cancer Res 2005; 65:1814-1821.
5. Malek RL, Irby RB, Guo QM, et al. Identification of Src transformation fingerprint in human colon cancer. Oncogene 2002; 21:7256-7265.
6. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002; 94:344-351.
7. Irby RB, Mao W, Coppola D, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999; 21:187-190.
8. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006; 66 :5542-5548.
9. Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006; 168:962-972.
10. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007.
11. Hiscox S, Morgan L, Green T, Nicholson RI. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocrine-Relat Cancer 2006; 13 (Suppl 1):S53-S59.
12. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007; 67:1580-1588.
13. Kotha A, Sekharam M, Cilenti L, et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 2006; 5:621-629.
14. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65:9185-9189.
15. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 2007; 11: 91-100.
16. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439:353-357.
17. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells. Cancer Res 2006; 66:11314-11322.
18. Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 2006; 66:2279-2286.
19. Boschelli DH, Ye F, Wang YD, et al. Optimization of 4-phenylamino-3- quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001; 44:3965-3977. (Pubitemid 33051486)
20. Trevino JG, Summy JM, Gallick GE. SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 2006; 6:681-687.
21. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21:7001-7010.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
23. Courtneidge SA. Role of Src in signal transduction pathways. The Jubilee Lecture. Biochem Soc Trans 2002; 30:11-17.
24. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000; 19:5636-5642.
25. Qi J, Wang J, Romanyuk O, Siu CH. Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Mol Biol Cell 2006; 17: 1261-1272.
26. Mirmohammadsadegh A, Hassan M, Bardenheuer W, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 2006; 126:2272-2280.
27. Criscuoli ML, Nguyen M, Eliceiri BP. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005; 105:1508-1514.
28. Samanna V, Wei H, Ego-Osuala D, Chellaiah MA. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res 2006; 312:2214-2230.
29. Chen J, Carcamo JM, Borquez-Ojeda O, Erdjument-Bromage H, Tempst P, Golde DW. The laminin receptor modulates granulocyte-macrophage colony-stimulating factor receptor complex formation and modulates its signaling. Proc Natl Acad Sci U S A 2003; 100:14000-14005.
30. Shellman YG, Park YL, Marr DG, et al. Release of vascular endothelial growth factor from a human melanoma cell line, WM35, is induced by hypoxia but not ultraviolet radiation and is potentiated by activated Ras mutation. J Invest Dermatol 2003; 121:910-917.
31. Niu G, Shain KH, Huang M, et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 2001; 61:3276-3280.
32. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer metastasis Rev 2005; 24:315-327.
33. Golas JM, Lucas J, Etienne C, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005; 65:5358-5364.
34. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007; 25:517-525.
35. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007; 67:2226-2238. (Pubitemid 46424242)
36. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007; 67 :2800-2808.